Since the publication of this research Article, we retrospected the paper and noticed two inadvertent mistakes that need to be corrected immediately. We have checked the original data and repeated the experiments; the correct data are provided in this Corrigendum as follows. The key findings of the article are not affected by these corrections.
Since the publication of this research Article, we retrospected the paper and noticed two inadvertent mistakes that need to be corrected immediately. We have checked the original data and repeated the experiments; the correct data are provided in this Corrigendum as follows. The key findings of the article are not affected by these corrections.
(1) In Fig. 1a , after repeating the experiment, we found that the PD-L1 expression in CT26 and B16-F10 cell lines are different from those before. We checked the original data and confirmed that there is something wrong. Thus, the original figure should be replaced as shown here. Therefore the sentence in the results about Fig. 1a : "The results showed that PD-L1 percentage is CT26 (26.65%) and B16-F10 (79.57%)", should be changed to "The results showed that PD-L1 percentage is CT26 (81.7%) and B16-F10 (44.9%)". However, immunohistochemistry analysis revealed approximately the same percentage of PD-L1 expression in clinical tissue samples, including colon cancer and melanoma. We think that the difference in expression levels of PD-L1 in tumor cell lines and clinical samples need to be investigated further.
(2) In Fig. 2b , the same pictures showed the proliferation of CD8 + PD-1 + TIL treated with supernatant from the C26-anti-PD-1 or C26-GM-CSF+anti-PD-1 vaccines, which is an inadvertent mistake. After checking the original data, we feel the figure should be as shown here.
We apologize for this omission. 
